Lecanemab approval in EU: what should we be ready for?- the EANM perspective.

Competing Interests: Declarations. Disclosures: AV has received honoraria for lectures and advisory board participation from Curium, Eisai, General Electrics and Novartis. MB received consulting/speaker honoraria from Life Molecular Imaging, GE healthcare, and Roche, and reader honoraria from Life Molecular Imaging. HB received consulting/speaker honoraria from Hermes Medical Solutions, IBA, Lilly, Eisai and Novartis/AAA, reader honoraria from Life Molecular Imaging, and dosing committee honoraria from Pharmtrace. DC has received research support and travel honoraria from General Electric and Life Molecular Imaging. DVW has received research support from General Electric and reader honoraria from Life Molecular Imaging. EG has received honoraria for consultation and advisory board participation from AAA/Novartis, Curium/LMI, General Electric, Keosys and Pfizer. NT is member of advisory board for Telix Pharmaceuticals and has in kind research support from Curium Pharma. TG has received consulting and lecture fees from Eisai and EliLilly; outside the submitted work, TG received consulting fees from AbbVie, Alector, Anavex, Biogen, BMS; Cogthera, Functional Neuromodulation, Grifols, Iqvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, Roche Pharma, UCB, and Vivoryon; lecture fees from Biogen, Grifols, Medical Tribune, Novo Nordisk, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen, Eisai, and Roche Diagnostics. IY has received consultant fees from ABX-CRO, Blue Earth Diagnostics, and Pentixapharm, and speaker honoraria from Piramal. The other authors have nothing to disclose.